Martin Capital Partners LLC Acquires 135,344 Shares of Pfizer Inc. $PFE

Key Points

• Martin Capital Partners LLC has significantly increased its holdings in Pfizer Inc. by 245.1%, acquiring an additional 135,344 shares, bringing its total to 190,573 shares valued at approximately $4.62 million.
• Pfizer reported strong earnings results, with $0.78 earnings per share for the last quarter, exceeding analysts' expectations, and revenue of $14.65 billion up 10.3% year-over-year.
• The company announced a quarterly dividend of $0.43, which represents an annualized yield of 7.2%, and has a dividend payout ratio of approximately 91.49%.

Martin Capital Partners LLC increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 245.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 190,573 shares of the biopharmaceutical company's stock after purchasing an additional 135,344 shares during the quarter. Pfizer makes up 1.8% of Martin Capital Partners LLC's investment portfolio, making the stock its 29th biggest holding. Martin Capital Partners LLC's holdings in Pfizer were worth $4,619,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock worth $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Northern Trust Corp grew its stake in shares of Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares during the last quarter. Amundi grew its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Pfizer by 3.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 39,402,619 shares of the biopharmaceutical company's stock worth $1,045,351,000 after purchasing an additional 1,333,740 shares during the last quarter. Finally, Invesco Ltd. grew its stake in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock worth $767,709,000 after purchasing an additional 838,198 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 3.8%

PFE opened at $23.91 on Monday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $30.43. The firm has a market capitalization of $135.94 billion, a PE ratio of 12.72, a P/E/G ratio of 0.85 and a beta of 0.55. The company's 50-day moving average is $24.79 and its 200 day moving average is $24.27.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the business posted $0.60 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. The ex-dividend date was Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Jefferies Financial Group upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Berenberg Bank cut their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Finally, HSBC cut their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.